Abstract
Immune thrombocytopenia is an immunologically determined disease characterized by platelet destruction and impaired production of platelets resulting to various grade of thrombocytopenia with or without bleeding symptoms. Currently we have both, traditional treatment targeted at inhibition of platelet destruction (corticosteroids, immunosuppression, splenectomy), and newer thrombopoietin receptor agonists increasing platelet production in the bone marrow.
For a group of relapsed and refractory patients, the outcomes of ongoing clinical trials using new drugs are promising. ITP treatment is based on the recommendations of expert groups.
The latest recommendations of the international group (International Consensus Report, ICR guidelines) and the American Society of Hematology (ASH guidelines) were published in 2019.